Introduction: Dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1)-dependent pathways in pancreatic neuroendocrine neoplasms (PanNENs) underlies the introduction of the mTORC1 inhibitor everolimus as treatment of advanced progressive PanNENs. Although everolimus significantly increases progression-free survival, most patients acquire secondary resistance to the drug. This study aimed at identifying mechanisms involved in acquisition of resistance to everolimus. Methods: BON-1 and everolimus-resistant (ER) BON-1 cells were used as in vitro system of sensitivity and acquired resistance. Transcriptome changes occurring in BON-1 and ER-BON-1 were investigated by RNA sequencing and validated by quantitative PCR analysis. RNA extracted from patients’ biopsies was used to validate MYC upregulation. Drug screening and functional assays were performed using ER-BON-1 cells. Cell cycle progression was evaluated by FACS analysis. Results: Our results show that MYC overexpression is a key event in the development of secondary resistance to everolimus in PanNEN cell lines and in metastatic lesions from neuroendocrine neoplasm patients. MYC knockdown restored ER-BON-1 sensitivity to everolimus. Pharmacological inhibition of MYC mediated by the cyclin-dependent kinase inhibitor dinaciclib strongly reduced viability of ER-BON-1. Dinaciclib synergized with everolimus and inhibited ER-BON-1 cell cycle progression. Discussion: Our findings suggest that MYC upregulation drives the development of secondary resistance to everolimus in PanNENs and that its inhibition is an exploitable vulnerability. Indeed, our results indicate that combined treatments with cyclin-dependent kinase and mTOR inhibitors may counteract secondary resistance to everolimus in PanNENs and may pave the ground for new therapeutic regimens for these tumors.

1.
Dasari
A
,
Shen
C
,
Halperin
D
,
Zhao
B
,
Zhou
S
,
Xu
Y
, et al.
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
.
JAMA Oncol
.
2017
Oct
;
3
(
10
):
1335
42
.
[PubMed]
2374-2437
2.
Merola
E
,
Rinzivillo
M
,
Cicchese
N
,
Capurso
G
,
Panzuto
F
,
Delle Fave
G
.
Digestive neuroendocrine neoplasms: A 2016 overview
.
Dig Liver Dis
.
2016
Aug
;
48
(
8
):
829
35
.
[PubMed]
1590-8658
3.
Falconi
M
,
Eriksson
B
,
Kaltsas
G
,
Bartsch
DK
,
Capdevila
J
,
Caplin
M
, et al.;
Vienna Consensus Conference participants
.
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors
.
Neuroendocrinology
.
2016
;
103
(
2
):
153
71
.
[PubMed]
0028-3835
4.
Capurso
G
,
Archibugi
L
,
Delle Fave
G
.
Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors
.
J Hepatobiliary Pancreat Sci
.
2015
Aug
;
22
(
8
):
594
601
.
[PubMed]
1868-6974
5.
Missiaglia
E
,
Dalai
I
,
Barbi
S
,
Beghelli
S
,
Falconi
M
,
della Peruta
M
, et al.
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway
.
J Clin Oncol
.
2010
Jan
;
28
(
2
):
245
55
.
[PubMed]
0732-183X
6.
Yao
JC
,
Shah
MH
,
Ito
T
,
Bohas
CL
,
Wolin
EM
,
Van Cutsem
E
, et al.;
RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
.
Everolimus for advanced pancreatic neuroendocrine tumors
.
N Engl J Med
.
2011
Feb
;
364
(
6
):
514
23
.
[PubMed]
0028-4793
7.
Pavel
ME
,
Hainsworth
JD
,
Baudin
E
,
Peeters
M
,
Hörsch
D
,
Winkler
RE
, et al.;
RADIANT-2 Study Group
.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
.
Lancet
.
2011
Dec
;
378
(
9808
):
2005
12
.
[PubMed]
0140-6736
8.
Panzuto
F
,
Rinzivillo
M
,
Fazio
N
,
de Braud
F
,
Luppi
G
,
Zatelli
MC
, et al.
Real-world study of everolimus in advanced progressive neuroendocrine tumors
.
Oncologist
.
2014
Sep
;
19
(
9
):
966
74
.
[PubMed]
1083-7159
9.
Panzuto
F
,
Cicchese
N
,
Partelli
S
,
Rinzivillo
M
,
Capurso
G
,
Merola
E
, et al.
Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms
.
PLoS One
.
2017
Jun
;
12
(
6
):
e0179445
.
[PubMed]
1932-6203
10.
Carew
JS
,
Kelly
KR
,
Nawrocki
ST
.
Mechanisms of mTOR inhibitor resistance in cancer therapy
.
Target Oncol
.
2011
Mar
;
6
(
1
):
17
27
.
[PubMed]
1776-2596
11.
Beyens
M
,
Vandamme
T
,
Peeters
M
,
Van Camp
G
,
Op de Beeck
K
.
Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors
.
Endocr Relat Cancer
.
2019
Mar
;
26
(
3
):
R109
30
.
[PubMed]
1351-0088
12.
Knudsen
JR
,
Fritzen
AM
,
James
DE
,
Jensen
TE
,
Kleinert
M
,
Richter
EA
.
Growth Factor-Dependent and -Independent Activation of mTORC2
.
Trends Endocrinol Metab
.
2020
Jan
;
31
(
1
):
13
24
.
[PubMed]
1043-2760
13.
Passacantilli
I
,
Capurso
G
,
Archibugi
L
,
Calabretta
S
,
Caldarola
S
,
Loreni
F
, et al.
Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition
.
Oncotarget
.
2014
Jul
;
5
(
14
):
5381
91
.
[PubMed]
1949-2553
14.
Gagliano
T
,
Bellio
M
,
Gentilin
E
,
Molè
D
,
Tagliati
F
,
Schiavon
M
, et al.
mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids
.
Endocr Relat Cancer
.
2013
Jun
;
20
(
4
):
463
75
.
[PubMed]
1351-0088
15.
Salazar
R
,
Garcia-Carbonero
R
,
Libutti
SK
,
Hendifar
AE
,
Custodio
A
,
Guimbaud
R
, et al.
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors
.
Oncologist
.
2018
Jul
;
23
(
7
):
766
e90
.
[PubMed]
1083-7159
16.
Matsumoto
M
,
Seike
M
,
Noro
R
,
Soeno
C
,
Sugano
T
,
Takeuchi
S
, et al.
Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
.
BMC Cancer
.
2015
Apr
;
15
(
1
):
241
.
[PubMed]
1471-2407
17.
Passacantilli
I
,
Panzeri
V
,
Terracciano
F
,
Delle Fave
G
,
Sette
C
,
Capurso
G
.
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death
.
Oncol Rep
.
2018
Apr
;
39
(
4
):
1984
90
.
[PubMed]
1021-335X
18.
Rahnenfuhrer, Adrian Alexa and Jorg. topGO: Enrichment Analysis for Gene Ontology.
2019
: R package version 2.36.0.
19.
Subramanian
A
,
Tamayo
P
,
Mootha
VK
,
Mukherjee
S
,
Ebert
BL
,
Gillette
MA
, et al.
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles
.
Proc Natl Acad Sci USA
.
2005
Oct
;
102
(
43
):
15545
50
.
[PubMed]
0027-8424
20.
Bihani
T
,
Ezell
SA
,
Ladd
B
,
Grosskurth
SE
,
Mazzola
AM
,
Pietras
M
, et al.
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers
.
Oncotarget
.
2015
Feb
;
6
(
4
):
2407
20
.
[PubMed]
1949-2553
21.
Chen
H
,
Liu
H
,
Qing
G
.
Targeting oncogenic Myc as a strategy for cancer treatment
.
Sig Transduct Target Ther
;
2018
. pp.
3
5
.
22.
Moharram
SA
,
Shah
K
,
Khanum
F
,
Marhäll
A
,
Gazi
M
,
Kazi
JU
.
Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia
.
Cancer Lett
.
2017
Oct
;
405
:
73
8
.
[PubMed]
0304-3835
23.
Carey
JP
,
Karakas
C
,
Bui
T
,
Chen
X
,
Vijayaraghavan
S
,
Zhao
Y
, et al.
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
.
Cancer Res
.
2018
Feb
;
78
(
3
):
742
57
.
[PubMed]
0008-5472
24.
Liu
S
,
Nikanjam
M
,
Kurzrock
R
.
Dosing de novo combinations of two targeted drugs: towards a customized precision medicine approach to advanced cancers
.
Oncotarget
.
2016
Mar
;
7
(
10
):
11310
20
.
[PubMed]
1949-2553
25.
Whitfield
JR
,
Beaulieu
ME
,
Soucek
L
.
Strategies to Inhibit Myc and Their Clinical Applicability
.
Front Cell Dev Biol
.
2017
Feb
;
5
:
10
.
[PubMed]
2296-634X
26.
Saunders
PO
,
Weiss
J
,
Welschinger
R
,
Baraz
R
,
Bradstock
KF
,
Bendall
LJ
.
RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine
.
Oncogene
.
2013
Oct
;
32
(
40
):
4789
97
.
[PubMed]
0950-9232
27.
Zhao
H
,
Li
S
,
Wang
G
,
Zhao
W
,
Zhang
D
,
Wang
F
, et al.
Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway
.
Cancer Med
.
2019
Aug
;
8
(
9
):
4348
58
.
[PubMed]
2045-7634
28.
Tan
J
,
Yu
Q
.
Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy
.
Chin J Cancer
.
2013
Jul
;
32
(
7
):
376
9
.
[PubMed]
1000-467X
29.
Liu
P
,
Ge
M
,
Hu
J
, et al.
A functional mTORC1 signaling is indispensable for c-Myc driven hepatocarcinogenesis
.
Hepatology
.
2017
;
66
(
1
):
167
81
.
[PubMed]
0270-9139
30.
Zeng
M
,
Kwiatkowski
NP
,
Zhang
T
,
Nabet
B
,
Xu
M
,
Liang
Y
, et al.
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
.
eLife
.
2018
Nov
;
7
:
7
.
[PubMed]
2050-084X
31.
Johnson
SF
,
Cruz
C
,
Greifenberg
AK
,
Dust
S
,
Stover
DG
,
Chi
D
, et al.
CDK12 INHIBITION REVERSES DE NOVO AND ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA WILD-TYPE AND MUTATED MODELS OF TRIPLE-NEGATIVE BREAST CANCER
.
Cell Rep
.
2016
Nov
;
17
(
9
):
2367
81
.
[PubMed]
2639-1856
32.
Horiuchi
D
,
Kusdra
L
,
Huskey
NE
,
Chandriani
S
,
Lenburg
ME
,
Gonzalez-Angulo
AM
, et al.
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
.
J Exp Med
.
2012
Apr
;
209
(
4
):
679
96
.
[PubMed]
0022-1007
33.
Scott
AT
,
Weitz
M
,
Breheny
PJ
,
Ear
PH
,
Darbro
B
,
Brown
BJ
, et al.
Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors
.
Clin Cancer Res
.
2020
Apr
;
26
(
8
):
2011
21
.
[PubMed]
1078-0432
34.
Grande
E
,
Teulé
A
,
Alonso-Gordoa
T
,
Jiménez-Fonseca
P
,
Benavent
M
,
Capdevila
J
, et al.
The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)
.
Oncologist
.
2020
Feb
;
•••
:
theoncologist.2020-0033
.
[PubMed]
1083-7159
35.
Kumar
SK
,
LaPlant
B
,
Chng
WJ
,
Zonder
J
,
Callander
N
,
Fonseca
R
, et al.;
Mayo Phase 2 Consortium
.
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
.
Blood
.
2015
Jan
;
125
(
3
):
443
8
.
[PubMed]
0006-4971
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.